21,267 results match your criteria British journal of haematology[Journal]


Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Hannover Medical School, Hannover, Germany.

Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long-term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous and solicited sources from 16 March 2007 through 1 October 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15790DOI Listing
February 2019

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15800DOI Listing
February 2019
1 Read

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Section of Haematology, Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.

Hodgkin Lymphoma (HL) is associated with deep microenvironment re-shaping and myeloid dysfunction. Given that only limited data are available regarding the role of Brentuximab Vedotin (BV) as single agent in transplant-naive relapsed/refractory (R/R) patients and its off-target effects on immune system, we evaluated the amount of regulatory T-cells (T-regs), myeloid-derived suppressor cells (MDSC) subpopulations, and their functional marker, serum arginase-1 (s-Arg-1), in peripheral blood of 15 consecutive R/R HL patients. After a median of four BV cycles, the overall response rate (complete response + partial response) was 47%, with 4 (27%) complete metabolic remissions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15801DOI Listing
February 2019

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre-National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15802
Publisher Site
http://dx.doi.org/10.1111/bjh.15802DOI Listing
February 2019
1 Read

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Celgene Corporation, Summit, NJ, USA.

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15797DOI Listing
February 2019
1 Read

Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88 detection in lymphomas with plasmacytic/plasmacytoid differentiation.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Institute of Pathology, Neuropathology and Molecular Pathology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15792DOI Listing
February 2019
1 Read

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15778DOI Listing
February 2019
1 Read

Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

University of Tennessee Health Science Center, Memphis, TN, USA.

In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low- and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15785DOI Listing
February 2019
1 Read

Clinical relevance of pulmonary vasculature involvement in sickle cell disease.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Department of Pathology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Pulmonary complications are frequent in patients with sickle cell disease (SCD), but few studies have described lung pathology in SCD. We studied the lung tissue of 30 deceased SCD patients (1994-2012). Demographics, genotype, clinical characteristics, cause of death and associated conditions are presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15795DOI Listing
February 2019
2 Reads

Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Division of Paediatric Haemato-Oncology, Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.

The 6th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) was held in Rotterdam, Netherlands, 26-29 September, 2018. This summary manuscript is a perspective on the presentations from the plenary scientific sessions, including wellness and survivorship, B-cell NHL, AYA lymphoma, translational NHL biology, lymphoma immunology, bone marrow transplantation and cell therapy, T/Natural Killer cell lymphoma, anaplastic large cell lymphoma, lymphoblastic lymphoma, novel lymphoma therapeutics and Hodgkin lymphoma. The symposium was attended by over 260 registrants from 42 different countries and included young, middle and senior investigators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15764DOI Listing
February 2019
1 Read

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Queen's University, Belfast, UK.

The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re-induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high-risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15782DOI Listing
February 2019
1 Read

Fibrin-associated diffuse large B-cell lymphoma.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Pathology Unit, Ospedale di Terni, University of Perugia, Terni, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15786DOI Listing
February 2019
1 Read

Artificial intelligence and machine learning in haematology.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Department of Haematology, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15774DOI Listing
February 2019

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Pädiatrische Hämatologie und Onkologie, Justus-Liebig-Universität Gießen and Medical Faculty of the Martin-Luther University of Halle, Germany.

The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th 2018 in Rotterdam, the Netherlands. This review summarizes some of those presentations, as well as other current and novel antibody therapy, immune check-point inhibitors, chimeric antigen receptor T cells, cancer vaccines and cytotoxic T lymphocyte therapy. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15789
Publisher Site
http://dx.doi.org/10.1111/bjh.15789DOI Listing
February 2019
8 Reads

The use of artificial neural network analysis can improve the risk-stratification of patients presenting with suspected deep vein thrombosis.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Headington, Oxford, UK.

Artificial neural networks are machine-learning algorithms designed to analyse data without a pre-existing hypothesis as to any associations that may exist. This technique has not previously been applied to the risk stratification of patients referred with suspected deep vein thrombosis (DVT). Current assessment is usually with a points-based clinical score, which may be combined with a D-dimer blood test. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15780
Publisher Site
http://dx.doi.org/10.1111/bjh.15780DOI Listing
February 2019
5 Reads

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Br J Haematol 2019 Feb 5. Epub 2019 Feb 5.

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA.

Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). Ofatumumab is a fully humanized anti-CD20 monoclonal antibody with increased CD20 affinity and complement-dependent cytotoxicity. This phase 2 trial (NCT01190449) evaluated ofatumumab in patients with untreated, low/intermediate-risk FL International Prognostic Index (FLIPI), advanced-stage FL to determine single-agent efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15768DOI Listing
February 2019
1 Read

Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?

Authors:
Gerhard Zugmaier

Br J Haematol 2019 Feb 5. Epub 2019 Feb 5.

Department of Haematology, Oncology and Immunology, Pilipps University Marburg, Marburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15769DOI Listing
February 2019

Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.

Progress in overall survival rates for childhood non-Hodgkin lymphoma (NHL) can be largely attributed to effective development and conduct of a number of international treatment studies. Knowledge gained from these studies has shifted the treatment paradigm from a "one-size fits all" strategy to a histologically dependent approach. More specifically, many now adhere to a risk-stratified approach, prescribing cumulative doses and intensities of chemotherapeutic exposures based upon the aggressiveness of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15775DOI Listing
February 2019
1 Read

Potential roles of artificial intelligence learning and faecal immunochemical testing for prioritisation of colonoscopy in anaemia.

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Department of Haemato-oncology, Barts Health NHS Trust, University Hospitals Plymouth NHS trust, London, UK.

Iron deficiency anaemia (IDA) is the most common cause of anaemia and a frequent indication for colonoscopy, although the prevalence of colorectal cancer (CRC) in IDA is low. Measurement of faecal haemoglobin by immunochemical techniques (FIT) is used to detect symptomatic patients. We studied FIT in patients with anaemia attending a gastroenterology clinic in Plymouth and looked at an artificial intelligence (AI) learning algorithm (ColonFlag™) in these patients, together with a cohort who had undergone colonoscopy for IDA in London. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15776DOI Listing
February 2019
1 Read

Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse.

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Department of Paediatric Oncology/Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Aneuploidy is common in paediatric B-cell precursor acute lymphoblastic leukaemia (ALL). Specific subgroups, such as high hyperdiploidy (>50 chromosomes or DNA Index ≥1·16) and hypodiploidy (<45 chromosomes), predict outcome of patients after primary treatment. Whether aneuploidy has a prognostic value for relapsed disease is yet to be determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15770DOI Listing
February 2019
2 Reads

Bittersweet news for the adult sickle cell patient.

Authors:
Deborah Rund

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Department of Haematology, Hebrew University-Hadassah Medical Organization, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15771DOI Listing
February 2019

Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.

Br J Haematol 2019 Feb 3. Epub 2019 Feb 3.

Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.

Conflicting evidence exists on the epidemiology of type 2 diabetes mellitus (T2DM) among patients with sickle cell disease (SCD). This study measured the prevalence, incidence and clinical outcomes associated with T2DM in a large US population of commercially-insured adults aged ≥20 years with SCD between 2009 and 2014. Among 7070 patients with SCD, the mean age (median) was 39 (37) years and 60·8% were female. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15773DOI Listing
February 2019
2 Reads

Developments beyond blood group serology in the genomics era.

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Clinical Services and Research, Australian Red Cross Blood Service, Kelvin Grove, Queensland, Australia.

Blood group serology and single nucleotide polymorphism-based genotyping platforms are accurate but do not provide a comprehensive cover for all 36 blood group systems and do not cover the antigen diversity observed among population groups. This review examines the extent to which genomics is shaping blood group serology. Resources for genomics include the Human Reference Genome Sequence assembly; curated blood group tables listing variants; public databases providing information on genetic variants from world-wide studies; and massively parallel sequencing technologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15747DOI Listing
February 2019

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Br J Haematol 2019 Jan 31. Epub 2019 Jan 31.

Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.

Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15777DOI Listing
January 2019
1 Read

Role for DNA base-excision repair gene variants in the prognosis of Hodgkin lymphoma.

Br J Haematol 2019 Jan 31. Epub 2019 Jan 31.

Laboratory of Cancer Genetics, Faculty of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15779DOI Listing
January 2019

Mature (non-anaplastic, non-cutaneous) T-/NK-cell lymphomas in children, adolescents and young adults: state of the science.

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Mature (non-anaplastic) T-cell and natural killer (NK)-lymphomas rarely occur in children or adolescents. Due to the low incidence and heterogeneity, information regarding the aetiology, physiopathology and genetics of paediatric mature (non-anaplastic) T/NK-cell lymphoma is lacking. In addition, standard treatments have not yet been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15767DOI Listing
February 2019
1 Read

Do we need cytogenetics in the follow-up of multiple myeloma?

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Section Multiple Myeloma, Department Haematology, Oncology and Rheumatology, University Hospital Heidelberg and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15781DOI Listing
February 2019

Treatment and prognosis of mature (non-anaplastic) T- and NK-cell lymphomas in childhood, adolescents, and young adults.

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Department of Haematology/Oncology, Shimane University Hospital, Izumo, Japan.

Paediatric non-Hodgkin lymphomas (pNHL) are a diverse group of malignancies characterised by nodal and/or extranodal involvement. Less common pNHL forms include those derived from mature T- and natural killer (NK) cells. Much of our current understanding of paediatric mature (non-anaplastic) T/NK-cell lymphomas with respect to pathogenesis, diagnosis and treatment is extrapolated from adult literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15772DOI Listing
February 2019
1 Read

Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2019 Jan 30. Epub 2019 Jan 30.

Department of Paediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies. Most NHLs in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi-agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long-term toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15783DOI Listing
January 2019
1 Read

Progress in the monitoring of direct oral anticoagulant therapy.

Br J Haematol 2019 Jan 29. Epub 2019 Jan 29.

Department of Haematological Medicine, King's Thrombosis Centre, King's College Hospital Foundation NHS Trust, London, UK.

The availability of direct oral anticoagulants (DOACs) has led to a paradigm shift in the field of anticoagulation, with DOACs increasingly being prescribed for patients in preference to vitamin K antagonists and low molecular weight heparin. Despite good experience with the use of these agents at fixed doses, there are clinical scenarios where monitoring is recommended. Data from phase III studies of the DOACs and small real-world studies suggest a relationship between DOAC concentration and clinical events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15756DOI Listing
January 2019

Intravenous iron treatment reduces coagulability in patients with iron deficiency anaemia: a longitudinal study.

Br J Haematol 2019 Jan 25. Epub 2019 Jan 25.

Internal Medicine C, Emek Medical Centre, Afula, Israel.

Although many case reports and observational studies have reported a correlation between iron deficiency anaemia (IDA) and thrombotic events, the mechanism for this is poorly understood. To evaluate this, we examined the change in coagulability in patients receiving treatment for IDA. Adult patients with IDA were recruited for this study and treated with intravenous iron. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15765DOI Listing
January 2019
2 Reads

Contribution of immunoglobulin lambda light chain gene rearrangement analysis in the diagnosis of B-cell neoplasms.

Br J Haematol 2019 Jan 25. Epub 2019 Jan 25.

Haematopathology and Oncology Diagnostics Service, Addenbrooke's Hospital, Cambridge University NHS Foundation Trust, Cambridge, UK.

Identification of clonal IGH, IGK and IGL gene rearrangements offers diagnostic adjunct in suspected B-cell neoplasms. However, many centres omit IGL analysis as its value is uncertain. A review of 567 cases with IGH, IGK and IGL rearrangement assessed using BIOMED-2 assays showed clonal immunoglobulin gene rearrangement in 54% of cases, of which 24% had a clonal IGL rearrangement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15762DOI Listing
January 2019
1 Read

From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.

Br J Haematol 2019 Jan 25. Epub 2019 Jan 25.

Department of Pathology, Division of Cellular and Molecular Pathology, University of Cambridge, Cambridge, UK.

Anaplastic large cell lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma that mainly presents in paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting in hyperactivation of anaplastic lymphoma kinase (ALK) as the consequence of a chromosomal translocation. Rarer cases lack expression of ALK fusion proteins and are categorised as ALCL, ALK-. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15763DOI Listing
January 2019
1 Read

Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.

Br J Haematol 2019 Jan 25. Epub 2019 Jan 25.

Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.

Loss of B cell-specific transcription factors (TFs) and the resulting loss of B-cell phenotype of Hodgkin and Reed-Sternberg (HRS) cells is a hallmark of classical Hodgkin lymphoma (cHL). Here we have analysed two members of ETS domain containing TFs, ELF1 and ELF2, regarding (epi)genomic changes as well as gene and protein expression. We observed absence or lower levels of ELF1 protein in HRS cells of 31/35 (89%) cases compared to the bystander cells and significant (P < 0·01) downregulation of the gene on mRNA as well as protein level in cHL compared to non-cHL cell lines. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15757
Publisher Site
http://dx.doi.org/10.1111/bjh.15757DOI Listing
January 2019
2 Reads
4.711 Impact Factor

How we manage patients with pyruvate kinase deficiency.

Br J Haematol 2019 Jan 25. Epub 2019 Jan 25.

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Novel therapies in development have brought a new focus on pyruvate kinase deficiency (PKD), the most common congenital haemolytic anaemia due to a glycolytic enzyme deficiency. With an improved recognition of its clinical presentation and understanding of the diagnostic pathway, more patients are likely to be identified with this anaemia. Complications, including gallstones and non-transfusion-related iron overload, require monitoring for early diagnosis and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15758DOI Listing
January 2019
1 Read

Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.

Br J Haematol 2019 Jan 24. Epub 2019 Jan 24.

Department of Paediatrics, University of Helsinki, Helsinki, Finland.

The population-based Nordic/Baltic acute lymphoblastic leukaemia (ALL) Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol combined minimal residual disease (MRD)-driven treatment stratification with very intense first line chemotherapy for patients with high risk ALL. Patients with MRD ≥5% at end of induction or ≥10 at end of consolidation or following two high risk blocks were eligible for haematopoietic cell transplantation (HCT) in first remission. After at least three high risk blocks a total of 71 children received HCT, of which 46 had MRD ≥5% at end of induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15761DOI Listing
January 2019
4 Reads

A personal dedication to Sir David J Weatherall GBE, FRS (9 March 1933-8 December 2018).

Br J Haematol 2019 Feb;184(3):319-320

Irish Blood Transfusion Service Cork, St. Finbarr's Hospital, Cork, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15755DOI Listing
February 2019
1 Read

Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma.

Br J Haematol 2019 Jan 17. Epub 2019 Jan 17.

Department of Haematology, Herlev Hospital, Herlev, Denmark.

Multiple myeloma (MM) is an incurable but treatment-sensitive cancer. For most patients, this means treatment with multiple lines of anti-myeloma therapy and a life with disease- and treatment-related symptoms and complications. Health-related quality of life (HRQoL) issues play an important role in treatment decision-making. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15759
Publisher Site
http://dx.doi.org/10.1111/bjh.15759DOI Listing
January 2019
5 Reads

Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis.

Br J Haematol 2019 Jan 17. Epub 2019 Jan 17.

Discipline Molecular Medicine and Pathology, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.

Chronic lymphocytic leukaemia (CLL) remains the most common incurable malignancy of B cells in the western world. Patient outcomes are heterogeneous and can be difficult to predict with current prognostic markers. Here, we used a quantitative label-free proteomic technique to ascertain differences in the B-cell proteome from healthy donors and CLL patients with either mutated (M-CLL) or unmutated (UM-CLL) IGHV to identify new prognostic markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15751DOI Listing
January 2019
3 Reads

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Br J Haematol 2019 Jan 13. Epub 2019 Jan 13.

King's College London, London, UK.

Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid-resistant graft-versus-host-disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical trials. Here, we present the UK experience of one of the largest cohorts of GvHD patients undergoing MSC infusions so far reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15749DOI Listing
January 2019
1 Read

Radiation exposure and longitudinal changes in peripheral monocytes over 50 years: the Adult Health Study of atomic-bomb survivors.

Br J Haematol 2019 Jan 13. Epub 2019 Jan 13.

Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan.

Enhanced inflammatory responses have been suggested decades after radiation exposure in atomic-bomb survivors, but cellular and molecular alterations related to prolonged inflammation remain unclear. This study, utilizing longitudinal haematological data over 50 years for 14 000 persons, investigated whether radiation exposure promoted the relative increase in peripheral myeloid cells, known as an aging-associated indicator of low-grade inflammation. Statistical modelling was performed with a linear mixed-effects model for leucocyte subsets, together with a proportional hazards regression model for all-cause mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15750DOI Listing
January 2019
1 Read

Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia.

Br J Haematol 2019 Jan 10. Epub 2019 Jan 10.

Department of Paediatric Haematology and Oncology, Schneider Children's Medical Centre of Israel, Petach Tivka, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

This study investigated the prevalence of inherited thrombophilia, risk of venous thromboembolism (VTE) and benefit of low molecular weight heparin prophylaxis in 476 Israeli children with acute lymphoblastic leukaemia (ALL) treated between 2004 and 2016. Thrombophilia was found in 15·5%. Arab children had a higher prevalence of F5 R506Q (factor V Leiden) than Jewish children (19·4% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15752DOI Listing
January 2019
2 Reads

Editorial change at BJH.

Authors:
John Barrett

Br J Haematol 2019 Jan;184(2):118

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15754DOI Listing
January 2019
1 Read